Pathologic response to neoadjuvant sequenced, lymphatic-sparing SBRT plus pembrolizumab in HPV-negative head and neck squamous cell carcinoma.R. Bryan Bell, Kristina H. Young, Steven K. Seung et al.|Journal of Clinical Oncology|2025Cited by 2
Neoadjuvant SBRT followed by evorpacept and pembrolizumab in HPV-mediated head and neck squamous cell carcinoma: Investigation of pathologic response.Joseph A. Califano, R. Bryan Bell, Andrew B. Sharabi et al.|Journal of Clinical Oncology|2025Cited by 0